Newsroom

Sorted by: Latest
-

AM Best to Exhibit at Florida Association of Insurance Agents’ 2026 Convention and Education Symposium

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best will be exhibiting during the Florida Association of Insurance Agents’ (FAIA) 122nd Convention and Education Symposium, which is scheduled to take place June 17–19, 2026, at the Gaylord Palms Resort & Convention Center in Orlando, FL.Visitors to the AM Best booth, which is No. 509, can learn about the rating agency, its role in the insurance industry and the resources it offers to insurance professionals, including Best’s Credit Ratings, Best’s Perform...
-

Shilpa Medicare与Gate2Brain签署战略股权合作协议，共同推进首创脑癌疗法

印度来楚尔和西班牙巴塞罗那--(BUSINESS WIRE)--(美国商业资讯)-- Shilpa Medicare Limited (BSE/NSE: SHILPAMED)子公司Shilpa Biocare Pvt Ltd已与专注于中枢神经系统(CNS)治疗的生物技术公司Gate2Brain, S.L.达成战略股权合作。Shilpa将成为Gate2Brain核心项目G2B-002的战略股东以及化学制造与控制(CMC)、生产和监管合作伙伴。G2B-002是Gate2Brain针对致命性儿童脑癌——弥漫性内桥脑胶质瘤(DIPG)和儿童胶质母细胞瘤(pGBM)的开发的核心管线，这两项适应症均已获得美国食品药品监督管理局(FDA)和欧洲药品管理局(EMA)的孤儿药资格认定。G2B-002利用Gate2Brain专有的MiniAp4多肽穿梭载体，将SN-38递送透过血脑屏障，在临床前研究中展现出高达100倍的脑部药物转运效率提升。首次人体临床试验预计将于2028财年启动。 G2B-002瞄准了高增长的肿瘤学市场——胶质母细胞瘤市场规模预计到2035年将达到64.8亿美元（年复合增长率7.97%...
-

Samenvatting: Shilpa Medicare en Gate2Brain sluiten strategisch aandelenpartnerschap om een baanbrekende behandeling voor hersenkanker te ontwikkelen

RAICHUR, India & BARCELONA, Spanje--(BUSINESS WIRE)--Shilpa Biocare Pvt Ltd, een dochteronderneming van Shilpa Medicare Limited (BSE/NSE: SHILPAMED), is een strategisch aandelenpartnerschap aangegaan met Gate2Brain, S.L., een biotechnologiebedrijf dat zich richt op geneesmiddelen voor het centrale zenuwstelsel. Shilpa wordt strategisch aandeelhouder en partner op het gebied van CMC, productie en regelgeving voor G2B-002. Dit is het belangrijkste programma van Gate2Brain gericht op DIPG en pGBM,...
-

Shilpa Medicare und Gate2Brain schließen strategische Kapitalpartnerschaft zur Weiterentwicklung einer bahnbrechenden Therapie gegen Hirntumore

RAICHUR, Indien & BARCELONA, Spanien--(BUSINESS WIRE)--Shilpa Biocare Pvt Ltd, eine Tochtergesellschaft von Shilpa Medicare Limited (BSE/NSE: SHILPAMED), ist eine strategische Kapitalpartnerschaft mit Gate2Brain, S.L., einem auf Therapeutika für das zentrale Nervensystem spezialisierten Biotechnologieunternehmen, eingegangen. Shilpa wird strategischer Anteilseigner sowie Partner für CMC, Herstellung und Zulassungsangelegenheiten für G2B-002 – das Leitprogramm von Gate2Brain zur Behandlung der t...
-

Shilpa Medicare et Gate2Brain concluent un partenariat stratégique avec prise de participation pour faire progresser un traitement de première classe contre le cancer du cerveau

RAICHUR, Inde et BARCELONE, Espagne--(BUSINESS WIRE)--Shilpa Biocare Pvt Ltd, filiale de Shilpa Medicare Limited (BSE/NSE : SHILPAMED), a conclu un partenariat stratégique avec prise de participation avec Gate2Brain, S.L., une société de biotechnologie spécialisée dans les traitements du système nerveux central. Shilpa devient ainsi actionnaire stratégique et partenaire CMC, de fabrication et de réglementation pour G2B-002, le programme phare de Gate2Brain ciblant des cancers cérébraux pédiatri...
-

Shilpa Medicare與Gate2Brain簽署策略股權合作協議，共同推進首創腦癌療法

印度賴久爾和西班牙巴塞隆納--(BUSINESS WIRE)--(美國商業資訊)-- Shilpa Medicare Limited (BSE/NSE: SHILPAMED)子公司Shilpa Biocare Pvt Ltd已與專注於中樞神經系統(CNS)治療的生物科技公司Gate2Brain, S.L.達成策略股權合作。Shilpa將成為Gate2Brain核心計畫G2B-002的策略股東以及化學製造與控制(CMC)、生產和監管合作夥伴。G2B-002是Gate2Brain針對致命性小兒腦癌——瀰漫性橋腦內生膠質瘤(DIPG)和小兒多形性膠質母細胞瘤(pGBM)的開發的核心研發產品線，這兩項適應症均已獲得美國食品藥物管理局(FDA)和歐洲藥品管理局(EMA)的孤兒藥資格認定。G2B-002利用Gate2Brain專有的MiniAp4胜肽載體，將SN-38傳輸透過血腦屏障，在臨床前研究中展現出高達100倍的腦部藥物轉運效率提升。首次人體臨床試驗可望於2028會計年度啟動。 G2B-002瞄準高成長腫瘤學市場——膠質母細胞瘤市場規模到2035年可望達到64.8億美元（年均複合成長率7.9...
-

Rosen Law Firm Urges GRAIL, Inc. (NASDAQ: GRAL) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GRAIL, Inc. (NASDAQ: GRAL) between May 13, 2025 and February 19, 2026, inclusive (the “Class Period”). GRAIL, Inc. is a commercial stage healthcare company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that GRAIL, Inc. (NASDA...
-

KBRA Assigns Preliminary Ratings to Jack in the Box Funding, LLC Series 2026-1 Senior Secured Notes

NEW YORK--(BUSINESS WIRE)--KBRA assigns preliminary ratings to Jack in the Box Funding, LLC Series 2026-1 Class A-1 and Class A-2 Notes, a whole business securitization (WBS). The rating actions follow KBRA’s analysis which indicates that existing credit enhancement for the notes and cash flows are sufficient to support the ratings following the issuance of the Series 2026- 1. In conjunction with the issuance of the Series 2026-1 Notes, the Series 2019-1 Class A-2-II and the Series 2022-1 Class...
-

JCR Pharmaceuticals’ Research Presentations at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders

HYOGO, Japan--(BUSINESS WIRE)--JCR presented new clinical data in a poster session at the 18th International Symposium on MPS and Related Lysosomal Diseases, held June 4-7, 2026....
-

Coast Guard Incident Commander for Operations and Historian Reveal the Untold Story of the JFK Jr. Search Mission in New Book, The Last Flight, Publishing October 13, 2026

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harper Select will publish The Last Flight: The Untold Story of the Search for JFK Jr. and the Race Against the Atlantic on October 13, 2026. Written by Captain W. Russell "Russ" Webster, the Coast Guard commander who led the search operation, and maritime historian Theresa Mitchell Webster, the book delivers the definitive account of the unprecedented multi-agency mission launched after John F. Kennedy Jr., his wife Carolyn Bessette Kennedy, and her sister La...